BioStem Technologies to Present at Two Upcoming Investor Conferences

BioStem Technologies Inc. (OTC: BSEM), a prominent MedTech company specializing in placental-derived biologics, is poised to showcase its advancements in advanced wound care at two significant investor conferences in New York. The first event is the Morgan Stanley Global Healthcare Conference, scheduled for Monday, September 8, 2025, where the company's management will engage in a fireside chat at 3:20 PM ET. Following this, BioStem will present at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025, at 11:00 AM ET.

Investors and interested parties will have the opportunity to access live and archived webcasts of these presentations through the investor section of BioStem’s website. The company encourages stakeholders to stay updated by joining its distribution list and following its social media channels, including X (formerly Twitter) and LinkedIn.

BioStem Technologies is dedicated to leveraging the unique properties of perinatal tissue for regenerative therapies. Central to its strategy is the proprietary BioREtain® processing method, developed to preserve growth factors and tissue structure, thus enhancing the effectiveness of its allografts. The company’s quality management systems comply with best practices and are accredited by the American Association of Tissue Banks (AATB), ensuring that all products are manufactured under stringent Good Tissue Practices (cGTP) and Good Manufacturing Processes (cGMP).

BioStem's product portfolio includes well-recognized brands such as AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. All products are processed at the company's FDA-registered facility in Pompano Beach, Florida. For more detailed information, stakeholders can visit the company's website and reach out via provided contact details.

BioStem Technologies Inc. (OTC: BSEM), a prominent player in the MedTech sector specializing in placental-derived biologics, is gearing up for significant visibility through its participation in two imminent investor conferences: the Morgan Stanley Global Healthcare Conference and the H.C. Wainwright 27th Annual Global Investment Conference. These platforms will provide BioStem management the opportunity to showcase its innovative advancements and longstanding commitment to enhancing regenerative therapies through its proprietary BioREtain® processing method.

Given the focus on advanced wound care, and the increasing global demand for effective therapeutic solutions, BioStem’s strategic positioning makes it an appealing investment prospect. The company’s compliance with rigorous standards set by the American Association of Tissue Banks (AATB) and adherence to current Good Tissue Practices (cGTP) and Good Manufacturing Practices (cGMP) highlight its commitment to quality and safety—key factors that bolster investor confidence.

Investors should closely monitor BioStem’s presentations at these conferences for insights into its product pipeline and market strategies. Engaging with management’s commentary could provide a clearer picture of future growth trajectories, as it aims to cultivate partnerships and expand market presence. Additionally, the company's focus on leveraging natural properties of perinatal tissue not only aligns with current trends in regenerative medicine but also opens up channels for diverse applications beyond wound care.

As BioStem Technologies connects with the broader investment community, stakeholders should consider the potential implications of its announcements for stock performance. Investors may find value in positioning themselves ahead of these conferences, given the heightened visibility and potential market enthusiasm that often follows such events. In summary, BioStem represents a compelling opportunity within the MedTech arena, particularly as it continues to innovate and expand its impactful product offerings.